184 related articles for article (PubMed ID: 27048105)
1. Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors.
Santotoribio JD; Garcia-de la Torre A; Cañavate-Solano C; Arce-Matute F; Sanchez-del Pino MJ; Perez-Ramos S
Eur J Gynaecol Oncol; 2016; 37(1):26-9. PubMed ID: 27048105
[TBL] [Abstract][Full Text] [Related]
2. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
4. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
5. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
6. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
Fan HY; Duan DM; Liu YF
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.
Zhang W; Jia S; Xiang Y; Yang J; Jia C; Leng J
J Int Med Res; 2019 Jan; 47(1):96-104. PubMed ID: 30198356
[TBL] [Abstract][Full Text] [Related]
9. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
10. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors.
Lertkhachonsuk AA; Buranawongtrakoon S; Lekskul N; Rermluk N; Wee-Stekly WW; Charakorn C
J Obstet Gynaecol Res; 2020 Nov; 46(11):2287-2291. PubMed ID: 32830422
[TBL] [Abstract][Full Text] [Related]
11. Total inhibin is a potential serum marker for epithelial ovarian cancer.
Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
[TBL] [Abstract][Full Text] [Related]
12. A giant ovarian mucinous tumor in a 58-year-old postmenopausal patient with persistent abdominal pain and high serum levels of CA 19-9.
Mulita F; Oikonomou N; Tchabashvili L; Liolis E; Kehagias I
Pan Afr Med J; 2020; 37():76. PubMed ID: 33244339
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
15. Appendiceal mucinous neoplasm mimics ovarian tumors: Challenges for preoperative and intraoperative diagnosis and clinical implication.
Zhang W; Tan C; Xu M; Wu X
Eur J Surg Oncol; 2019 Nov; 45(11):2120-2125. PubMed ID: 31462390
[TBL] [Abstract][Full Text] [Related]
16. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
Cho HY; Kyung MS
Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
[TBL] [Abstract][Full Text] [Related]
17. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
18. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
19. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
Shin JE; Choi HJ; Kim MH; Cho KS
Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
[TBL] [Abstract][Full Text] [Related]
20. Mucinous carcinoma of the ovary. Clinicopathologic analysis.
Kikkawa F; Kawai M; Tamakoshi K; Suganuma N; Nakashima N; Furuhashi Y; Kuzuya K; Hattori S; Arii Y; Tomoda Y
Oncology; 1996; 53(4):303-7. PubMed ID: 8692534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]